Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

A new report from Renub Research forecasts that the diabetes device market in China will grow from US$6.22 billion in 2023 to US$12.74 billion by 2032, representing a compound annual growth rate (CAGR ...

On its way out the door, the Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs ...

As we have entered into the new year 2025, here's a recap of 2024's economy and healthcare with key areas to look in global ...

The drugmaker launched a campaign supporting its weight loss medication Contrave, all backed by a cover version of Lesley ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.64% and ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...